Mark is a medically-qualified (specialist training in anaesthesia and critical care) and GMC-registered drug developer with 25 years' pharmaceutical R&D experience. Formerly, he was a Global Clinical R&D Director and then Director of Science and Medical Public Affairs at Pfizer in Sandwich, Kent. He has worked at all phases of clinical development across a wide variety of therapeutic areas. This includes regulatory product approval experience, having successfully led Pfizer's global clinical development team to achieve the US/EU registration of sildenafil as a first-in-class treatment for pulmonary arterial hypertension.
His experience has also included the establishment of major R&D projects at the interfaces between academia, the NHS and the biopharmaceutical industry e.g. having helped lead the establishment of 1) MRC/industry pre-competitive consortia in COPD and RA and 2) the UK Government's Translational Research Partnership Programme.
Now he provides strategic and applied clinical, scientific and policy advice to life sciences organisations throughout the public, private and charitable sectors. He was R&D Director of The Ethical Medicines Industry Group (EMIG) for which he established de novo a strong scientific & medical arm to complement the commercial interests of the association. This was pivotal to grow and diversify EMIG's membership to include a broad range of charitable organisations in addition to biopharma.
Mark is a Non-Executive Director of the SW Academic Health Science Network (SWAHSN).
